Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Massimo Lemoli

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialMarco Ladetto, Katja Gutmair, Rita Tavarozzi, et al.
Blood Advances|February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
American Journal of Hematology|September 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell TransplantationFabio Guolo, Luana Fianchi, Maria Paola Martelli, et al.
Hematological Oncology|July 20, 2022
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COVPatrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialMarco Ladetto, Katja Gutmair, Rita Tavarozzi, et al.
Blood Advances|February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
American Journal of Hematology|September 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell TransplantationFabio Guolo, Luana Fianchi, Maria Paola Martelli, et al.
Hematological Oncology|July 20, 2022
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COVPatrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, et al.
Pageof 5